Connect with us

Technology

Clinical Trial Management System (CTMS) Market size is set to grow by USD 1.86 billion from 2024-2028, Increasing healthcare expenditure to boost the market growth, Technavio

Published

on

NEW YORK, July 30, 2024 /PRNewswire/ — The global clinical trial management system (CTMS) market size is estimated to grow by USD 1.86 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 14.27% during the forecast period. Increasing healthcare expenditure is driving market growth, with a trend towards increasing outsourcing of clinical trial process. However, rising cost of clinical trials poses a challenge. Key market players include Advarra Inc., ArisGlobal LLC, Clinion Inc., Crucial Data Solutions Inc., Dassault Systemes SE, DATATRAK International Inc., DSG Inc., Ennov SAS, eResearchTechnology GmbH, International Business Machines Corp., Laboratory Corp. Of America Holdings, MasterControl Solutions Inc., Medfiles USA, MedNet, Oracle Corp., Parexel International Corp., PHARMASEAL, RealTime Software Solutions LLC, Veeva Systems Inc., and Wipro Ltd..

Get a detailed analysis on regions, market segments, customer landscape, and companies – Click for the snapshot of this report

Forecast period

2024-2028

Base Year

2023

Historic Data

2018 – 2022

Segment Covered

Deployment (On-premise and Cloud), End-user (Pharmaceutical and biotechnology companies, CROs, and Others), and Geography (North America, Europe, Asia, and Rest of World (ROW))

Region Covered

North America, Europe, Asia, and Rest of World (ROW)

Key companies profiled

Advarra Inc., ArisGlobal LLC, Clinion Inc., Crucial Data Solutions Inc., Dassault Systemes SE, DATATRAK International Inc., DSG Inc., Ennov SAS, eResearchTechnology GmbH, International Business Machines Corp., Laboratory Corp. Of America Holdings, MasterControl Solutions Inc., Medfiles USA, MedNet, Oracle Corp., Parexel International Corp., PHARMASEAL, RealTime Software Solutions LLC, Veeva Systems Inc., and Wipro Ltd.

 

Key Market Trends Fueling Growth

In the pharmaceutical industry, the shift towards outsourcing drug discovery processes to subcontract laboratories has been a significant trend since 2011. This transformation has enabled small companies to focus on manufacturing and marketing activities while outsourcing research and testing to external resources. The increasing popularity of this approach is due to the substantial cost savings it offers, as companies can outsource these functions for a fraction of the cost of building and maintaining their own research facilities. This outsourcing trend is particularly prevalent in countries like the US, the UK, Germany, and Japan, which have been outsourcing drug discovery to emerging economies such as India and Brazil. The high volume of data generated during the drug discovery process necessitates the use of Clinical Trial Management Systems (CTMS) to manage and analyze this data effectively. The growing number of tests carried out in subcontract laboratories has led to a corresponding increase in demand for CTMS solutions. CTMS plays a crucial role in streamlining the clinical trial process, ensuring compliance with regulatory requirements, and facilitating data management and analysis. As the outsourcing trend continues, the demand for CTMS is expected to grow, providing opportunities for market expansion. 

The Clinical Trial Management System (CTMS) market is experiencing significant trends that are transforming the clinical trial landscape. Robust reporting and centralizing recruitment are key priorities for multinational companies and local CROs. ERegulatory, eSOURCE, accounting, and aggregate reporting provide network-wide visibility and oversight. Digitalization, personalized medicine, outsourcing, and externalization are driving growth in the market. Robust reporting, decentralized trial models, and evidence-based facilities are essential for regulatory compliance. ERegulatory, ERT, and Bioclinica are leading providers in Healthcare IT. Cloud-based CTMS, telemedicine solutions, and decentralized clinical trials are crucial in the current COVID-19 era. Costs, system security, backups, upgrades, and uptime consistency are critical considerations for CTM systems. AI and machine learning are enhancing trial efficiency and reducing costs. Vaccines and CTM systems are essential in the fight against COVID-19. The market is expected to continue growing, with investment in digitalization and regulatory policies being key drivers. 

Discover 360° analysis of this market. For complete information, schedule your consultation- Book Here!

Market Challenges

Clinical trials are a crucial part of bringing new drugs to market, but their rising costs are a significant concern for the pharmaceutical industry. One major challenge is patient enrollment and retention, which can prolong the trial duration and increase expenses. According to various studies, the average cost per patient in the US for clinical trials is approximately USD41,117, with phase 3 trials being the most expensive, costing around USD20 million. Another factor contributing to the rising costs is the need for extensive clinical data collection due to new regulations. This can make trials complex and expensive, especially for drugs targeting chronic diseases. The longer a trial lasts, the more it costs, making clinical trial management systems essential to streamline the process. However, some clinical research associates may prefer manual work to cut costs, hindering the growth of the market. To address this issue, increasing patient awareness is the most feasible solution. By educating patients about the importance and benefits of clinical trials, the number of willing participants is likely to rise, reducing the overall cost and duration of trials. Pharmaceutical companies should focus on patient education rather than persuasion to ensure a successful clinical trial process.In the dynamic healthcare IT landscape, Clinical Trial Management Systems (CTMS) have become essential tools for managing complex clinical trials. However, implementing CTMS comes with challenges. Decentralized trials and the rise of vaccines require cloud-based CTMS for flexibility. Telemedicine solutions and COVID-NMA necessitate robust system security, backups, and upgrades. Centralization of data, growth, and AI/machine learning algorithms demand uptime consistency and automation. Clinical trial managers need access to data on devices like mobile workstations, laptops, and tablets via online dashboards. Trial planning, monitoring activities, regulatory procedures, supplies, finance, and subscription-based software upgrades require scalability. Add-ons, regulatory norms, document management processes, data quality, participant safety, and adherence to regulatory procedures are key considerations. Solutions like Clinion offer IWRS/RTSM, EDC, eCOA, accruals, deviations, and scalability to address these challenges.

For more insights on driver and challenges – Download a Sample Report

Segment Overview 

This clinical trial management system (ctms) market report extensively covers market segmentation by

Deployment 1.1 On-premise1.2 CloudEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 CROs2.3 OthersGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 On-premise- The Clinical Trial Management System (CTMS) market primarily consists of on-premises and cloud-based deployment models. On-premises CTMS offers enhanced data security and control, making it a preferred choice for large firms. However, the significant investment required for infrastructure and maintenance poses a challenge for smaller organizations. Conversely, cloud-based CTMS offers cost-effectiveness and ease of use. Major on-premises CTMS vendors include Siebel and IMPACT. Despite the high cost, large firms continue to prefer on-premises CTMS due to the perceived level of data security. This segment’s growth in the global CTMS market is anticipated to be driven by these factors during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2018 – 2022) – Download a Sample Report

Research Analysis

The Clinical Trial Management System (CTMS) market is a significant segment of Healthcare IT, facilitating the planning, execution, and management of clinical trials. With the increasing focus on decentralized clinical trials and the development of vaccines, CTMS solutions have gained prominence. Cloud-based CTMS is a popular choice due to its accessibility, scalability, and cost-effectiveness. Telemedicine solutions and IWRS/RTSM integrate seamlessly with CTMS, enhancing trial efficiency. EDC, eCOA, accruals, deviations, and robust reporting are essential features. Outsourcing and externalization to multinational companies and local CROs are common practices. Regulatory policies necessitate investment in CTMS solutions for ensuring compliance. Clario and other advanced systems offer features like ERT, making trial management more streamlined.

Market Research Overview

The Clinical Trial Management System (CTMS) market in Healthcare IT is experiencing significant growth due to the increasing adoption of decentralized clinical trials, particularly in the development of vaccines. Cloud-based CTMS solutions are gaining popularity for their accessibility and cost-effectiveness. Telemedicine solutions and AI-driven technologies, including machine learning algorithms and automation, are being integrated into CTMS to improve efficiency and data quality. Costs, system security, backups, and upgrades are key considerations for CTMS implementation. Uptime consistency, centralization of data, and regulatory norms are crucial for ensuring trial integrity and participant safety. Clinical trial managers require access to real-time data from devices such as mobile workstations, laptops, tablets, and online dashboards for effective trial planning, monitoring activities, and regulatory procedures. CTMS systems include modules for supplies, finance, and accounting on a subscription basis, with software upgrades and add-ons available for customization. Digitalization of clinical trials through eRegulatory, eSOURCE, IWRS/RTSM, EDC, eCOA, accruals, deviations, and scalable, robust reporting is driving growth in the market. Centralizing recruitment and network-wide visibility are also important for oversight and personalized medicine initiatives. Outsourcing and externalization to local CROs and multinational companies are common practices in the industry. Clario and other trial models are embracing decentralized approaches and evidence-based facilities to streamline regulatory policies and investment in the sector.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

DeploymentOn-premiseCloudEnd-userPharmaceutical And Biotechnology CompaniesCROsOthersGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/clinical-trial-management-system-ctms-market-size-is-set-to-grow-by-usd-1-86-billion-from-2024-2028–increasing-healthcare-expenditure-to-boost-the-market-growth-technavio-302208770.html

SOURCE Technavio

Continue Reading

Technology

3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development

Published

on

By

ST. PAUL, Minn., Oct. 19, 2026 /PRNewswire/ — 3M (NYSE: MMM) today announced a collaboration with Genius Electronic Optical Co., Ltd. (GSEO, Taiwan: 3406), an optical technology company, to advance technology development and manufacturing for 3M’s Expanded Beam Optical (EBO) solutions. In support of these efforts, 3M expects to make a strategic investment to acquire approximately 4.7% of GSEO’s common shares as part of the company’s private placement of newly issued shares, subject to customary closing conditions.

The collaboration brings together 3M’s EBO technology leadership, optical interconnect expertise, materials science, manufacturing scale and customer relationships with GSEO’s precision optics manufacturing capabilities and production scale. Together, the companies aim to support EBO commercialization and long-term capacity expansion to meet growing demand from hyperscale data centers and other advanced connectivity applications.

“3M is investing in capabilities and partnerships that can accelerate innovation for our customers,” said William Brown, 3M Chairman and CEO. “By selecting GSEO as a manufacturing partner and investing in the company, we are strengthening the path to scale next-generation optical connectivity solutions for high-performance data center infrastructure.”

GSEO’s existing precision optics manufacturing capabilities and technical development experience are expected to support manufacturing readiness for 3M’s EBO ferrules, co-packaged optics solutions and related optical interconnect applications. The collaboration is part of 3M’s broader EBO ecosystem strategy, which includes continued work with customers and partners across the optical interconnect market.

“GSEO is pleased to expand its relationship with 3M as we work together to advance optical interconnect solutions for next-generation data center infrastructure,” said Micro Kuo, GSEO CEO and President. “This collaboration brings together complementary technology and manufacturing strengths to support continued innovation and help meet the performance demands of high-growth connectivity markets.”

3M expects the strategic investment to close in the fourth quarter of 2026, subject to customary closing conditions.

Forward-Looking Statements
Certain statements in this release are considered “forward-looking statements” under the federal securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, and are intended to enjoy the protection of those laws. Forward-looking statements may appear throughout this release and are typically identified by the words “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “forecast,” “future,” “goal,” “guidance,” “impact,” “initial,” “intend,” “likely,” “may,” “outlook,” “plan,” “possible,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and other words that are similar to, or have the opposite meanings of, those words. Forward-looking statements speak only as of the date they are made, 3M assumes no duty to update those statements, and readers are cautioned not to place undue reliance on any of those statements. Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” of 3M’s Form 10-K for the year ended December 31, 2025.

About 3M
3M (NYSE: MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3M.com/news.

Contacts
3M
Investor Contact:
Diane Farrow, 612-202-2449
Media Contact:
3MNews@mmm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-announces-collaboration-with-gseo-to-advance-expanded-beam-optical-manufacturing-and-development-302913170.html

SOURCE 3M Company

Continue Reading

Technology

Scott Vicknair Personal Injury Lawyers Announces Second Annual Operation Fur-Ever Home Pet Adoption Event at Lafreniere Park

Published

on

By

NEW ORLEANS, Oct. 19, 2026 /PRNewswire/ — Scott Vicknair Personal Injury Lawyers is excited to announce the return of its second annual Operation Fur-Ever Home, a free community pet adoption event taking place on Saturday, November 14, 2026, from 9:00 a.m. to 11:00 a.m. at Lafreniere Park in Metairie, Louisiana.

The free, family-friendly event will give attendees the opportunity to meet adoptable pets from local animal shelters, learn about responsible pet ownership, and potentially welcome a new furry companion into their homes. Those who preregister for the event will also be entered for a chance to win a Soundcore speaker and a free pet adoption.

“Last year’s event was everything we hoped it would be, and we are incredibly excited to bring Operation Fur-Ever Home back for a second year,” said David Vicknair, founding partner of Scott Vicknair Personal Injury Lawyers. “There is something special about watching a family meet a pet that could become part of their lives for years to come. We wanted to create another opportunity to make those connections while supporting the organizations that work tirelessly to care for animals in our community.”

Building on the success of the first event, this year’s event continues the firm’s commitment to supporting local animal shelters and creating meaningful opportunities for families throughout Southeast Louisiana.

“Giving back to our community has always been an important part of who we are as a firm,” said Vicknair. “Whether we are helping students prepare for school, recognizing deserving teachers, or supporting local animal shelters, our goal is to make a positive difference in the communities we serve.”

Operation Fur-Ever Home is free and open to the public. Families, animal lovers, and anyone interested in adopting a pet are encouraged to attend and preregister.

About Scott Vicknair Personal Injury Lawyers

Scott Vicknair Personal Injury Lawyers is a New Orleans-based personal injury firm committed to providing exceptional legal representation while also investing in the communities it serves. Their experienced team of dedicated attorneys specializes in car accidents, personal injury, and wrongful death cases in New Orleans. With diverse personal and professional backgrounds, they craft legal strategies tailored to each client’s specific case and needs.

View original content:https://www.prnewswire.com/news-releases/scott-vicknair-personal-injury-lawyers-announces-second-annual-operation-fur-ever-home-pet-adoption-event-at-lafreniere-park-302913183.html

SOURCE Scott Vicknair Personal Injury Lawyers

Continue Reading

Technology

Can we produce low-cost omega-3s without relying on fish?

Published

on

By

GOLD COAST, Australia, Oct. 19, 2026 /PRNewswire/ — Southern Cross University researchers are aiming to halve the cost of producing omega-3 supplements to make these essential nutrients more accessible to pregnant women and infants in low-income countries, backed by the University’s first-ever grant from The Gates Foundation.

The research takes a novel approach: rather than relying on fish oil, the team is going closer to the original source of omega-3. Fish don’t produce omega-3 themselves – they accumulate it from marine microorganisms lower in the food chain.

Led by Professor Dirk Erler from Southern Cross University’s Faculty of Science and Engineering, the team is investigating how these naturally omega-3-producing microorganisms can be grown more cheaply through precision fermentation, including the use of agricultural and food-processing by-products as a source of fermentation sugar.

Omega-3 is an important nutrient during pregnancy and early life, supporting brain and nervous system development in babies. But the cost of supplements remains a significant barrier to access in many low-income countries.

“The main barrier for the uptake of omega-3s as supplements in pregnant women is the cost,” Professor Erler said.

“The whole objective of our project is to reduce that cost and make omega-3 supplements more available.”

The research team at Southern Cross University, which includes biomedical scientist Dr Nedeljka Rosic, Dr Shane McIntosh, postdoctoral researcher Dr Jasmine Haskell and PhD researcher Michael Ingram, is focused on growing omega-3-producing marine microorganisms known as thraustochytrids – or ‘throstys’ for short.

“By growing those microorganisms on land through precision fermentation, we have an alternative way of producing omega-3s that is both reliable and highly targeted,” Professor Erler said.

Precision fermentation allows the researchers to grow thraustochytrids under controlled conditions to produce omega-3 oils. The team is investigating whether expensive feedstocks used in the process can be replaced with lower-cost agricultural and food-processing by-products, helping drive down the overall cost of production.

The approach could also reduce reliance on wild-caught fish as a source of omega-3 oil and create a more reliable, scalable, and local supply.

For biomedical scientist Dr Nedeljka Rosic, the production challenge is ultimately about what greater access to omega-3 could mean for women and babies.

“As a biomedical scientist, my purpose is to find ways to use science to improve people’s health,” Dr Rosic said.

“This project is important because it aims to improve the health of pregnant women and children and reduce preterm births through simple dietary improvements.”

View original content to download multimedia:https://www.prnewswire.com/news-releases/can-we-produce-low-cost-omega-3s-without-relying-on-fish-302893631.html

SOURCE Southern Cross University

Continue Reading

Trending